Division of Nephrology, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Nephrology (Carlton). 2021 Feb;26(2):153-163. doi: 10.1111/nep.13782. Epub 2020 Oct 22.
Haemodialysis treatment prescription varies widely internationally. This study explored patient- and centre-level characteristics associated with weekly haemodialysis hours.
Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry data were analysed. Characteristics associated with weekly duration were evaluated using mixed-effects linear regression models with patient- and centre-level covariates as fixed effects, and dialysis centre and state as random effects using the 2017 prevalent in-centre haemodialysis (ICHD) and home haemodialysis (HHD) cohorts. Evaluation of patterns of weekly duration over time analysed the 2000 to 2017 incident ICHD and HHD cohorts.
Overall, 12 494 ICHD and 1493 HHD prevalent patients in 2017 were included. Median weekly treatment duration was 13.5 (interquartile range [IQR] 12-15) hours for ICHD and 16 (IQR 15-20) hours for HHD. Male sex, younger age, higher body mass index, arteriovenous fistula/graft use, Aboriginal and Torres Strait Islander ethnicity and longer dialysis vintage were associated with longer weekly duration for both ICHD and HHD. No centre characteristics were associated with duration. Variability in duration across centres was very limited in ICHD compared with HHD, with variation in HHD being associated with state. Duration did not vary significantly over time for ICHD, whereas longer weekly HHD treatments were reported between 2006 and 2012 compared with before and after this period.
This study in the Australian and New Zealand haemodialysis population showed that weekly duration was primarily associated with patient characteristics. No centre effect was demonstrated. Practice patterns seemed to differ across states/countries, with more variability in HHD than ICHD.
血液透析治疗方案在国际上差异很大。本研究探讨了与每周血液透析时间相关的患者和中心特征。
对澳大利亚和新西兰透析和移植(ANZDATA)登记处的数据进行了分析。使用混合效应线性回归模型,以患者和中心水平的协变量作为固定效应,以透析中心和州作为随机效应,评估与每周持续时间相关的特征,该模型纳入了 2017 年现患中心血液透析(ICHD)和家庭血液透析(HHD)队列的患者-和中心水平的协变量。通过分析 2000 年至 2017 年新发 ICHD 和 HHD 队列,评估每周持续时间随时间的变化模式。
2017 年共纳入 12494 例 ICHD 和 1493 例 HHD 现患患者。ICHD 的中位每周治疗时间为 13.5 小时(四分位距 [IQR] 12-15 小时),HHD 为 16 小时(IQR 15-20 小时)。男性、年龄较小、身体质量指数较高、动静脉瘘/移植物使用、原住民和托雷斯海峡岛民种族以及透析时间较长与 ICHD 和 HHD 的每周治疗时间延长相关。没有中心特征与持续时间相关。与 HHD 相比,ICHD 中心间的持续时间差异非常有限,而 HHD 的差异与州有关。ICHD 的持续时间在时间上没有显著变化,而在这段时间前后,每周 HHD 治疗时间更长。
本研究对澳大利亚和新西兰血液透析人群进行了研究,表明每周持续时间主要与患者特征相关。没有表现出中心效应。实践模式似乎因州/国家而异,HHD 的变化比 ICHD 更大。